FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Extending its gene-editing patent licences into research services, animals and therapeutics. Also seen: Discovery · preclinical

  • Signed a CRISPR RNP patent licence with Bioneer. Source
  • Signed a co-development deal with GenEditBio for in vivo gene-editing therapies. Source

Roles often seen at this stageBD & licensing · Research & development · Regulatory affairs

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

ToolGen

A company that licenses its CRISPR gene-editing patents and high-precision editing technology to research, therapeutic, animal and plant partners and co-develops with them.

CRISPR RNP patents

Technology platform

A core CRISPR RNP patent portfolio, now licensed into research gene-editing services.

Sniper 2L

Technology platform

A next-generation high-precision gene-editing technology with higher targeting accuracy and fewer off-target edits.

GEB-200

Stage unconfirmed

An in vivo gene-editing therapy co-developed with Hong Kong-based GenEditBio that lowers Lp(a) for atherosclerotic cardiovascular disease; a non-human primate proof-of-concept study is complete.

Completion reported

Granted Bioneer a non-exclusive licence to its CRISPR RNP patents and added the Sniper 2L line to an existing licence.

Completion reported

Signed a cross-licence with Hong Kong lipid-nanoparticle company GenEditBio to co-develop in vivo gene-editing therapies.

Completion reported

Licensed CRISPR-Cas9 technology to Avinogen for developing new bird varieties.

Official role guide

ToolGen careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 3

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 툴젠, 바이오니아와 CRISPR RNP 라이선스 계약 체결 ↗히트뉴스 · Published 2026-11-02 · Sources checked 2026-11-18 · Original unavailable
  2. 툴젠, 홍콩 지질나노입자 업체와 상호기술이전계약체결…생체내 유전자교정 치료제 개발 ↗한국경제 · Published 2025-11-24 · Sources checked 2026-11-18 · Original unavailable
  3. 툴젠, 조류 신품종 개발 위해 아비노젠에 유전자 교정기술 기술이전 ↗한국경제 · Published 2025-11-06 · Sources checked 2026-11-18 · Original unavailable